Analysts have a consensus target price of $ 10.22 in the 12-month period. The price objective is 208.76% higher than the recent closing price of $ 3.31. The 52-week price range is $ 1.69 – 6.69 and the company has a market capitalization of $ 72.72M. Analysts covering the shares maintain a consensus Strong Buy rating, according to Zacks Investment Research. zero analyst has rated the stock with a sell rating, zero has assigned a hold rating, 1 says it’s a buy, and 1 have assigned a strong buy rating to the company.
Vericel Corp (VCEL) on April 4, 2016 announced the presentation and publication of results from the company’s Phase 2b ixCELL-DCM clinical study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM). The data were presented today by Timothy Henry, M.D., at the Late-Breaking Clinical Trial Session and press conference at the American College of Cardiology’s (ACC) 65th Annual Scientific Session and published in The Lancet. Dr. Henry is director of cardiology at Cedars-Sinai Heart Institute, principal investigator of the study and co-author of the Lancet publication.
“The ixCELL-DCM study met its primary endpoint of demonstrating a reduction in the total number of all-cause deaths, cardiovascular hospitalizations, or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment with ixmyelocel-T compared to placebo,” said Dr. David Recker, Vericel’s chief medical officer. “From a safety perspective, the incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to or lower than patients in the placebo group. We are very excited about the results of this clinical trial and greatly appreciate the contributions of the patients, investigators and dedicated personnel who participated in this study.”
“We have a major unmet need in the treatment of class III and IV heart failure,” said Amit N. Patel, M.D., director of clinical regenerative medicine and associate professor of surgery at the University of Utah and the Chair of the ixCELL-DCM Steering Committee. “Based on these positive results, we are encouraged that ixmyelocel-T has the potential, if approved, to represent an important new option for patients with class III and class IV heart failure due to ischemic cardiomyopathy.”
The ixCELL-DCM clinical trial is a multicenter, randomized (1:1), double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to subjects with end-stage heart failure due to ischemic DCM. A total of 126 patients with New York Heart Association (NYHA) Class III or IV heart failure were randomly assigned to receive either ixmyelocel-T or placebo, and 114 patients were treated at 28 sites in the United States. All clinical events in the primary and secondary endpoints were adjudicated in a blinded fashion by an independent adjudication committee.
0 yorum:
Yorum Gönder